A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma

International Journal of Radiation Oncology, Biology, Physics, Volume 97, Issue 3, 2017 Mar 1 | Shenouda, George, MBBCh, PhD, FRCP; Souhami, Luis, MD, FASTRO; Petrecca, Kevin, MD;...
Summary Fifty patients with newly diagnosed glioblastoma were accrued on a phase 2 study of neoadjuvant temozolomide (TMZacrnm1) administered starting 3 weeks from surgery for 2 weeks prior to delivery of hypofractionated accelerated radiation the...

http://ift.tt/2jTJVxJ